Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase II Study
Allergy · 2025-01 · 80 (1) · 227-237
DOI: 10.1111/all.16404 ↗At a glance
Multizentrische Studie in Allergy, published online on 2024-12-14. Written by Sayantani B Sindher and 20 co-authors. Institution: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Peanut Hypersensitivity, Antibodies, Monoclonal, Anti-Allergic Agents. Cited 54 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Sanofi and Regeneron Pharmaceuticals Inc..
Topics: Kinderkrankenpflege
Abstract (original language)
Background
Peanut allergy is a potentially life‐threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)‐4/IL‐13, improved safety and desensitization to peanut exposure in children with peanut allergy.
Methods
A Phase II, 24‐week, multicenter, single‐arm, open‐label, proof‐of‐concept study was conducted in the USA and Canada (NCT03793608). Children/adolescents with peanut allergy received subcutaneous dupilumab 300 mg (≥ 60 kg) or 200 mg (≥ 20 to < 60 kg) every 2 weeks. The primary endpoint was the proportion of participants who passed a double‐blind placebo‐controlled food challenge (DBPCFC) with ≥ 444 mg (cumulative) of peanut protein at week 24. Secondary endpoints included safety measures (Consortium of Food Allergy Research grading system) and change from baseline in peanut‐specific (ps)‐IgG4, total IgE, and ps‐IgE.
Results
Twenty‐four participants enrolled and received dupilumab: 75.0% were male, 79.2% were white, mean (standard deviation) age was 11.7 (3.3) years. Most (95.8%) participants had not received allergen immunotherapy. Two participants (8.3%) achieved the primary endpoint and passed the DBPCFC at week 24. Fifteen participants (62.5%) reported 66 treatment‐emergent adverse events, all being mild or in moderate intensity. At the week 24 DBPCFC, 8 participants (33.3%) had a grade 2 allergic reaction (no grade 3 or above); 10 (41.7%) used adrenaline as a rescue medication. Dupilumab treatment resulted in a median reduction of total and ps‐IgE of −54% and −49%, respectively, and a 0% change in ps‐IgG4.
Conclusions
Dupilumab monotherapy treatment for 24 weeks did not improve desensitization to peanut exposure after food challenge.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.
- Harvard School of Public Health, Boston, Massachusetts, USA.
- Allergy & Immunology Association of Michigan, Ypsilanti, Michigan, USA.
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
- Division of Allergy and Immunology, Children's Hospital at Montefiore, Bronx, New York, USA.
ORCID profiles: Sayantani B Sindher, Kari C Nadeau, R Sharon Chinthrajah, Erik Wambre, Jamie M Orengo, Jennifer D Hamilton
Funding
- Sanofi and Regeneron Pharmaceuticals Inc.
Cite
APA
Sindher, S. B., Nadeau, K. C., Chinthrajah, R. S., Leflein, J. G., Bégin, P., Ohayon, J. A., Ponda, P., Wambre, E., Liu, J., Khokhar, F. A., Akinlade, B., Maloney, J., Orengo, J. M., Hamilton, J. D., Kamal, M. A., Hooper, A. T., Patel, N., Patel, K., Laws, E., …, & Radin, A. R. (2025). Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase II Study. Allergy, 80(1), 227-237. https://doi.org/10.1111/all.16404
Vancouver
Sindher SB, Nadeau KC, Chinthrajah RS, Leflein JG, Bégin P, Ohayon JA, et al. Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase II Study. Allergy. 2025;80(1):227-237. doi:10.1111/all.16404
BibTeX
@article{Sindher2025,
author = {Sindher, Sayantani B and Nadeau, Kari C and Chinthrajah, R Sharon and Leflein, Jeffrey G and Bégin, Philippe and Ohayon, Jason A and Ponda, Punita and Wambre, Erik and Liu, Jinzhong and Khokhar, Faisal A and Akinlade, Bolanle and Maloney, Jennifer and Orengo, Jamie M and Hamilton, Jennifer D and Kamal, Mohamed A and Hooper, Andrea T and Patel, Naimish and Patel, Kiran and Laws, Elizabeth and Mannent, Leda P and Radin, Allen R},
title = {Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase II Study},
journal = {Allergy},
year = {2025},
volume = {80},
number = {1},
pages = {227--237},
doi = {10.1111/all.16404}
}
EUVIMED